Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic radiofrequency ablation.

David A Iannitti1, Damian E Dupuy, William W Mayo-Smith

  • 1Department of Surgery, Brown University School of Medicine, Rhode Island Hospital, Providence, RI, USA. Diannitti@usasurg.org

Archives of Surgery (Chicago, Ill. : 1960)
|April 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia.

Scientific reports·2026
Same author

Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers.

Clinical pharmacology in drug development·2026
Same author

Treatment of non-effusive feline infectious peritonitis using oral remdesivir or GS-441524: a randomized, double-blind, non-inferiority trial.

Journal of feline medicine and surgery·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Beyond macrophages: FIPV tropism includes T and B lymphocytes.

Veterinary microbiology·2026
Same author

A brief visual evoked potential (VEP) modulation assessment of experience-dependent plasticity recorded via wireless dry-EEG headset in Phase 1 clinical units.

Scientific reports·2026
Same journal

The White Test: A New Dye Test for Intraoperative Detection of Bile Leakage During Major Liver Resection-Invited Critique.

Archives of surgery (Chicago, Ill. : 1960)·2017
Same journal

Use of Vascular Clamping in Hepatic Surgery: Lessons Learned From 1260 Liver Resections-Invited Critique.

Archives of surgery (Chicago, Ill. : 1960)·2017
Same journal

Randomized Clinical Trial of Small-Incision and Laparoscopic Cholecystectomy in Patients With Symptomatic Cholecystolithiasis: Primary and Clinical Outcomes-Invited Critique.

Archives of surgery (Chicago, Ill. : 1960)·2017
Same journal

Liver Resection With a New Multiprobe Bipolar Radiofrequency Device-Invited Critique.

Archives of surgery (Chicago, Ill. : 1960)·2017
Same journal

Porcine and Bovine Surgical Products: Jewish, Muslim, and Hindu Perspectives-Invited Critique.

Archives of surgery (Chicago, Ill. : 1960)·2017
Same journal

Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply.

Archives of surgery (Chicago, Ill. : 1960)·2016
See all related articles

Hepatic radiofrequency ablation (RFA) effectively treats unresectable liver tumors. Patient selection is crucial for optimal outcomes, though further trials are needed to confirm long-term survival benefits.

Area of Science:

  • Interventional Radiology
  • Oncology
  • Hepatology

Background:

  • Unresectable hepatic malignancies pose significant treatment challenges.
  • Hepatic radiofrequency ablation (RFA) is an emerging therapeutic option.

Purpose of the Study:

  • To evaluate the efficacy and safety of hepatic radiofrequency ablation (RFA) for unresectable liver tumors.
  • To assess patient selection criteria and outcomes.

Main Methods:

  • A case series of 123 patients with unresectable hepatic tumors treated with RFA.
  • Procedures involved a 200-W cooled-tip RF probe system, monitored by real-time ultrasonography or CT.
  • Median follow-up was 20 months.

Main Results:

Related Experiment Videos

  • 168 RFA sessions were performed between 1998 and 2001.
  • Mean tumor size was 5.2 cm; common diagnoses included metastatic colorectal cancer and hepatocellular carcinoma.
  • Overall morbidity was 7.1%, with complications including hepatic abscesses and transient liver insufficiency.

    • Conclusions:

    • Hepatic RFA is a viable and effective treatment for unresectable liver malignancies.
    • Careful patient selection based on tumor characteristics and clinical status is essential.
    • Further controlled trials are warranted to establish the long-term survival impact of RFA.